timothy sykes logo
REPL Stock Plunges As FDA Rejection Triggers Legal And Wall Street Backlash Thumbnail
G Google News

REPL Stock Plunges As FDA Rejection Triggers Legal And Wall Street Backlash

TIM SYKES•UPDATED MAY. 5, 2026, 11:32 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Replimune Group Inc. stocks have been trading down by -10.07 percent after disappointing trial data undermined investor confidence.

Candlestick Chart

Live Update At 11:32:22 EDT: On Tuesday, May 05, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending down by -10.07%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

REPL has turned into a classic fallen‑biotech chart. On 2026/04/10, the stock closed at $4.76 after the first big FDA shock. Since then, Replimune Group Inc. has bled lower, trading recently around the mid‑$2s, with closes between $2.38 and $3.03 over the past few weeks.

The daily candles show sharp gaps and long intraday ranges around the news, then a drifting, low‑volume grind. That tells traders the “event” move already happened, and now REPL is in the digestion phase where bounces and fades are both possible. Intraday, the 5‑minute data for the latest session show Replimune Group Inc. pushing from about $3.02 in premarket to a high near $3.09, then fading to a $2.73 close — a steady intraday downtrend.

Fundamentally, REPL is still a development‑stage biotech. Replimune Group Inc. posted a quarterly net loss of about $70.9M, with heavy R&D spend of $53.1M and negative operating cash flow of roughly $65.9M. The company ended the period with about $124.7M in cash and $269.1M in cash plus short‑term investments, and a strong current ratio of 5.6. That gives REPL runway, but the negative returns on equity and assets show how dependent the story was on RP1’s success.

Why Traders Are Watching REPL After The FDA Shock

REPL is now a case study in regulatory risk. Replimune Group Inc. had pinned its lead story to RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma. The FDA’s Complete Response Letter flatly rejected the Biologics License Application, saying the data were not enough to prove the drug works. The stock dropped almost 20% on high volume before trading was halted — a clear sign that traders rushed for the exits.

The hit didn’t stop there. Replimune Group Inc. later disclosed that this was actually the second Complete Response Letter for the same RP1 combination. A new FDA review team not only said no again, it effectively reversed earlier guidance that had allowed a single‑arm IGNYTE trial and an accelerated‑approval path. For REPL traders, that is critical: it means the old playbook for getting RP1 across the finish line is broken.

Management then acknowledged that without timely accelerated approval, continuing RP1 development is not viable. Replimune Group Inc. plans job cuts and major reductions in U.S. manufacturing operations. That signals a shrinking pipeline footprint and, for many on the Street, a weaker long‑term growth story. The second CRL also convinced HC Wainwright to double downgrade Replimune Group Inc. from Buy to Sell, while Cantor Fitzgerald, Piper Sandler, and JPMorgan all moved to more cautious stances.

On top of this, law firms Pomerantz LLP and Johnson Fistel launched investigations into possible securities fraud and whether Replimune Group Inc. misled markets about fixing the FDA’s concerns. Whether anything comes of those probes is unknown, but legally driven headlines often keep pressure on a stock and add another layer of uncertainty for REPL trading.

More Breaking News

Conclusion

For active traders, REPL sits in the danger zone where broken biotech stories sometimes become opportunity — but just as often turn into slow bleeds. Replimune Group Inc. still has a solid cash cushion and trades around book value, yet its core RP1 thesis has been hit hard by two FDA Complete Response Letters and a clear message that the IGNYTE trial design does not meet today’s bar for approval.

That is why analyst sentiment around Replimune Group Inc. has reset to a cautious Hold with a low single‑digit price target. The big, high‑conviction bull case that once surrounded RP1 is gone for now. Instead, the tape shows a stock that collapses on news and then grinds as traders scalp volatility while the company reassesses strategy and cuts costs.

For those who follow Tim Sykes‑style trading, this is the type of chart you study, not marry. As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. As Tim likes to say, “I’m not here to be right, I’m here to trade what’s actually happening and cut losses fast when I’m wrong.” Applied to REPL, that means respecting the downside created by regulatory and legal overhangs, watching Replimune Group Inc. for clean technical setups, and remembering that this is educational research — not a green light to blindly buy any biotech dip.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading REPL

Millionaire's
POV on REPL

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”